Drug details

Opfolda (miglustat capsules)

type of Enzyme Inhibitors

Opfolda (miglustat) is an enzyme stabilizer indicated, in combination with Pombiliti, a hydrolytic lysosomal glycogen-specific enzyme, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing 40 kg or more and who are not improving on their current enzyme replacement therapy (ERT).

This drug may have the following side effects:

• nausea,
• itching,
• rash,
• diarrhea,
• fever,
• shortness of breath,
• chills,
• dizziness,
• headache,
• fatigue,
• flushing,
• abdominal pain,
• muscle spasms,
• bloating,
• changes in taste,
• fast heart rate, and
• hives.

The following drugs are related to Opfolda, either as a replacement or used together:

• Myozyme (alglucosidase alfa)
• Lumizyme (alglucosidase alfa)
• Nexviazyme (avalglucosidase alfa-ngpt for injection)
• Pombiliti (cipaglucosidase alfa-atga for injection)